Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Southwestern Regional Medical Center
For resectable patient; surgery with Intraoperative Radiation Therapy (IORT). Radiation Therapy within 6-8 weeks after surgery followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery.
For marginally resectable patients; the patients will have 2-3 cycles of neoadjuvant chemotherapy of FOLFIRINOX and then restaged, undergo surgery with IORT within 2-4 weeks following chemotherapy. Then radiation therapy starting within 6-8 weeks. Followed by FOLFIRINOX every 2 weeks starting within 12 weeks of surgery for a total of 2-4 cycles.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically proven Exocrine Adenocarcinoma of the pancreas
Clinically resectable or marginally resectable disease
No prior radiation or chemotherapy for carcinoma of the pancreas
ECOG performance status of 0-1
Patients must be medically able to undergo surgical resection
Patients of child bearing potential must follow study specific precautions
Women that are lactating will not be excluded on the condition that they dispose their breast milk.
Adequate hematologic and biochemical parameters.
You may not be if
Prior treatment for pancreatic cancer.
Concurrent investigational treatments.
Unresectable pancreatic mass.
Neuroendocrine Histological pancreatic cancer
Distant Metastatic disease
Any condition that, in the option of the investigator, would compromise the well being of the patient or anything that would prevent the patient from meeting or performing study requirements
